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Abstract
Background and Aims—While a diet rich in anti-oxidant has been favorably associated with
coronary disease and hypertension, limited data have evaluated the influence of such diet on
subclinical disease. Thus, we sought to examine whether chocolate consumption is associated with
calcified atherosclerotic plaque in the coronary arteries (CAC).
Methods—In a cross-sectional design, we studied 2,217 participants of the NHLBI Family Heart
Study. Chocolate consumption was assessed by a semi-quantitative food-frequency questionnaire
and CAC was measured by cardiac CT. We defined prevalent CAC using an Agatston score of at
least 100 and fitted generalized estimating equations to calculate prevalence odds ratios of CAC.
Results—There was an inverse association between frequency of chocolate consumption and
prevalent CAC. Odds ratios (95% CI) for CAC were 1.0 (reference), 0.94 (0.66-1.35), 0.78
(0.53-1.13), and 0.68 (0.48-0.97) for chocolate consumption of 0, 1-3 times per month, once per
week, and 2+ times per week, respectively (p for trend 0.022), adjusting for age, sex, energy
intake, waist-hip ratio, education, smoking, alcohol consumption, ratio of total-to-HDL-
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cholesterol, non-chocolate candy, and diabetes mellitus. Controlling for additional confounders
did not alter the findings. Exclusion of subjects with coronary heart disease or diabetes mellitus
did not materially change the odds ratio estimates but did modestly decrease the overall
significance (p = 0.07).
Conclusions—These data suggest that chocolate consumption might be inversely associated
with prevalent CAC.
Keywords
Chocolate; diet; epidemiology; coronary calcium; subclinical disease
Introduction
It has been shown that the extent of calcified atherosclerotic plaque in the coronary arteries
(CAC) is highly correlated with total burden of atherosclerotic plaques1,2 The degree of
CAC -- measured by cardiac CT -- provides more prognostic information on coronary heart
disease (CHD) incidence3-5 and CHD mortality6,7. A diet rich in fruit and vegetables, dark
chocolate, or red wine – all good sources of flavonoids – has been associated with a lower
risk of CHD, cardiovascular mortality, lower blood pressure, and inhibition of platelet
aggregation8-12. In a cross-over study, consumption of 100 g/d of dark chocolate was
associated with a statistically significant reduction in systolic blood pressure in 13
hypertensive subjects after 14 days of intervention10. Another study also demonstrated
beneficial effects of dark chocolate on blood pressure in healthy subjects after 2 weeks of
intervention13. However, no previous study has evaluated whether frequent chocolate
consumption is associated with subclinical disease. In the present study, we used data
collected on 2,217 participants of the National Heart, Lung, and Blood Institute (NHLBI)
Family Heart Study (FHS) to determine whether chocolate consumption was associated with
a lower prevalence of CAC.
Materials and Methods
Study population
Participants in this project were members of the NHLBI FHS in whom coronary calcified
plaque was measured by cardiac gated multi-detector computed tomography (cardiac CT).
The NHLBI FHS is a multi-center, population-based study designed to identify and evaluate
genetic and non-genetic determinants of CHD, preclinical atherosclerosis, and
cardiovascular risk factors. Detailed descriptions of the NHLBI FHS have been published.
14,15 Briefly, families in the study had been chosen randomly (random group) or based on a
higher than expected risk of CHD (high-risk group) from previously established population-
based cohort studies. A total of 588 families were chosen at random (with 2673 subjects)
and 566 families were selected based on higher than expected risk of CHD (3037 subjects).
O the 5710 subjects, 265 were African-American. The high-risk group was defined based on
a family risk score, which compares the family's age and sex-specific incidence of CHD to
that expected in the general population.16 All members of these families were invited for a
clinical evaluation (between 1993 and 1995). Between 2002 and 2003, about one-third of the
families (the largest families available who also had genome-wide anonymous markers
typed by the Mammalian Genotyping Service) of the NHLBI FHS – including 9 African-
American participants – were invited to participate in a clinical examination that included
measurement of CAC with cardiac CT. In addition to the initial NHLBI FHS study centers,
an all African-American center – University of Alabama at Birmingham – was recruited
from the Hypertension Genetic Epidemiology Network Study, where subjects underwent
cardiac CT but did not have dietary assessments. Of the 3,370 subjects who had data on
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cardiac CT, 2,217 subjects also had complete data on chocolate consumption at baseline
examination (1993-1995). Each participant gave informed consent and the study protocol
was reviewed and approved by each of the participating institutions.
Assessment of chocolate consumption
Dietary information was collected through a staff-administered semi-quantitative food
frequency questionnaire developed by Willett et al.17. The reproducibility and validity of the
food frequency questionnaire has been documented elsewhere18,19. Each subject was asked
the following question: “In the past year, how often on average did you consume chocolate
bars or pieces, such as Hershey's Plain, M & M, Snickers, Reeses; 1 oz?” (Item # 39 in the
questionnaire forms). Possible responses were: “> 6 per day, 4-6 per day, 2-3 per day, 1 per
day, 5-6 per week, 2-4 per week, 1 per week, 1-3 per month, and almost never”. There were
very few people consuming more than 1 per day and since the odds ratios were similar
between 5-6/week and 1+/day as well as between 1/week and 2-4/week, we combined those
categories to obtain stable estimates.
Measurement of calcified atherosclerotic plaque in the coronary arteries
Cardiac CT examinations were obtained using General Electric Health Systems LightSpeed
Plus and LightSpeed Ultra, Siemens Volume Zoom, or Philips MX 8000 machines.
Examinations were performed using the same protocol as employed in the NHLBI's Multi-
Ethnic Study of Atherosclerosis.20 The scans were performed using prospective ECG gating
at 50% of the cardiac cycle, 120 KV, 106 mAs, 2.5 mm slice collimation, 0.5 second gantry
rotation and a partial scan reconstruction resulting in a temporal resolution of between
250-300 msec. Images were reconstructed using the standard algorithm into a 35 cm display
field-of-view. All subjects were imaged with a calcium calibration standard within the
imaging field (Image Analysis, Columbia, KY). The scan through the heart was repeated
after a one-minute pause during the same examination, resulting in two sequential scans for
measurement of CAC. The effective radiation exposure for the average participant of each
coronary scan was 1.5 mSv for men and 1.9 mSv for women. CT images from all sites were
sent electronically to the central CT reading center located at Wake Forest University Health
Sciences, Winston Salem, NC. Trained CT analysts using dedicated hardware (GE
Advantage Windows Workstation) and software (GE SmarScore) identified CAC in the
epicardial coronary arteries and an Agatston score modified to account for slice thickness
was calculated using a 130 CT number threshold and a minimum lesion size of 0.9 mm (i.e.,
2 pixel connectivity filter). Agatston score refers to the amount of calcium detected by the
scan and is based on the area and the density of the calcified plaques21. In this report, the
sum of the vessel plaque is reported as the total CAC score. Total CAC scores from the first
and second measured were then averaged.
For these analyses, we dichotomized the distribution of CAC score at an Agatston score of
100 or more as described previously15 and because this cut point has a reasonable sensitivity
and specificity.3 Nevertheless, we conducted sensitivity analyses to assess the robustness of
our findings to different cutoff points (CAC score of 0, 50, 150, 200, and 300) to define the
presence of calcified atherosclerotic plaque.
Blood collection and assays
All participants were asked to fast for twelve hours before their arrival at the study center.
Evacuated tubes without additives were used to collect samples for lipids. Triglyceride
concentrations were measured using triglyceride GB reagent on the Roche COBAS FARA
centrifugal analyzer (Boehringer Mannheim Diagnostics, Indianapolis). Serum total
cholesterol was measured using a commercial cholesterol oxidase method on a Roche
COBAS FARA centrifugal analyzer (Boehringer Mannheim Diagnostics, Indianapolis).
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HDL-cholesterol quantification was performed with the above described cholesterol method
after precipitation of non-HDL-cholesterol with magnesium/dextran. For samples with
triglycerides concentrations less than 4.5 mmol/L (400 mg/dL), LDL-cholesterol was
calculated using the Friedewald formula.22 For subjects with higher levels of triglycerides,
LDL-cholesterol quantitation was performed on EDTA plasma by ultracentrifugation.
Other variables
Information on cigarette smoking, alcohol intake, and education was obtained by interview
during the clinic visit. Resting blood pressure was measured three times on seated
participants after a 5-minute rest using a random zero sphygmomanometer and an
appropriate cuff size. For analyses, the average systolic and diastolic blood pressures from
the second and third measurements were used. We used the seventh Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
classification to define hypertension (stages 1 or 2 – systolic blood pressure of at least 140
mm Hg or diastolic blood pressure of at least 90 mm Hg) or if the subject reported that, he/
she was currently being treated for hypertension. Dietary information was obtained using a
food frequency questionnaire. Level of physical activity during the previous year was
estimated through self-reports. Anthropometric data were collected with participants
wearing scrub suits. Diabetes mellitus was considered present if a subject was taking
hypoglycemic agents, if a physician had told the subject that he/she had diabetes mellitus, or
if fasting glucose was above 7 mmol/L. Individuals were defined as a case of CHD if there
was a self-reported history of myocardial infarction, percutaneous transluminal coronary
angioplasty, or coronary artery bypass graft. All variables used in these analyses were
ascertained during the initial examination (1993-1995) except for CAC scores, which were
obtained during a follow-up examination (2002-2003).
Statistical analyses
We initially conducted sex-specific analyses, but since we observed similar inverse
association between chocolate consumption and CAC in men (p for trend 0.02) and women
(p for trend 0.03), we present combined data. We initially examined the distribution of CAC
cases according to all possible responses for chocolate consumption (Never, 1-3/month, 1/
week, 2-4/week, 5-6/week, 1/d, 2-3/d, 4-6/d, and >6/d). However, there were not enough
cases of CAC beyond consumption of 2-4 per week to have separate categories above this
level of chocolate intake. Thus, we used 4 categories of chocolate consumption (none, 1-3
times per month, once per week, and 2+ times per week) and created 3 indicator variables
using never consumption of chocolate as reference. We used univariate analyses to evaluate
potential confounders and used partial likelihood ratio tests to compare multivariable
regression models. The initial model only adjusted for age. Additional models controlled for
1) age, sex, smoking, and energy (6 categories); 2) age, sex, smoking, energy, waist-hip
ratio, education (3 groups), ratio of total-to-HDL-cholesterol, alcohol consumption, non-
chocolate candy consumption, and diabetes mellitus. The full model also controlled for field
center, CHD family risk group, body mass index, hypertension, triglycerides, weight loss
diet, and exercise. Additional adjustment for antioxidant vitamins (E, C, multivitamins),
wine, and beer consumption did not alter the results (data not shown). Because subjects were
not independent, we used generalized estimating equations to control for familial clustering
(exploring different correlation matrix structures). P values for linear trend were obtained by
creating a new variable that was assigned values of 0, 1, 2, and 3 to chocolate consumption
of never, 1-3 per month, 1 per week, and 2+ per week, respectively, and including the new
variable in the regression model. We conducted sensitivity analyses by a) restricting
analyses to Caucasians, b) excluding subjects with CHD, and c) using different cut points to
define CAC (0, 50, 100, 150, 200, and 300). Alpha level was set at 0.05 for statistical
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significance. All analyses were performed using windows SAS version 9.1 (SAS Institute
Inc, Cary, NC).
Results
Of the total 2,217 subjects, 44% were men and the mean age was 50.7±13.0 years (range
25.6 to 85.7 years). Table 1 shows the baseline characteristics by categories of chocolate
consumption. Chocolate consumption was associated with younger age, higher body mass
index, higher energy intake, higher intake of dietary linolenic acid, cholesterol, and saturated
fat, lower HDL, and lower consumption of fruit and vegetables and they consumed less wine
and vitamin E. In addition, subjects reporting chocolate consumption were less likely to
have hypertension or clinically diagnosed CHD. There was evidence for an inverse
association between chocolate consumption and prevalent CAC. Compared to subjects
reporting no chocolate intake, multivariable adjusted odds ratio (95% CI) for CAC of 100 or
greater were 0.95 (0.66-1.36), 0.79 (0.54-1.15), and 0.69 (0.48-0.99) among subjects
reporting chocolate consumption of 1-3 times per month, once per week, and 2 or more
times per week, respectively (p for linear trend 0.029, Table 2), adjusting for age, sex,
smoking, energy, waist-hip ratio, education, ratio of total-to-HDL cholesterol, alcohol
intake, non-chocolate candy, diabetes mellitus, study center, family CHD risk group, body
mass index, triglycerides, exercise, and current weight loss diet. Additional control for fruit
and vegetables, antioxidant vitamins (C, E, multivitamins), or red wine consumption (as
another source of polyphenols) did not alter the findings (data not shown).
Sensitivity analyses
There was evidence for an inverse association between chocolate consumption and prevalent
CAC when different cut points (50, 150, 200, and 300) were used to define the presence of
CAC (Figure 1). However, no association was seen when using an Agatston score of 0 to
define prevalent CAC (Figure 1). Inclusion of dietary cholesterol in the fully adjusted model
did not attenuate the results [ORs: 1.0, 0.96 (0.67-1.37), 0.81 (0.55-1.17), and 0.68
(0.47-0.98) from the lowest to the highest category of chocolate intake, respectively (p for
trend 0.023)]. When restricted to white participants, multivariable adjusted odds ratios were
1.0, 0.97 (0.68-1.39), 0.81 (0.55-1.18), and 0.70 (0.49-1.00) from the lowest to the highest
category of chocolate consumption, respectively (p for linear trend 0.033). After exclusion
of subjects with prevalent CHD (including prior myocardial infarction, angioplasty, or
coronary bypass surgery), corresponding odds ratios were 1.0, 1.00 (0.68-1.47), 0.83
(0.54-1.27), and 0.72 (0.48-1.07), respectively, (p for trend 0.07) and after exclusion of
subjects with CHD or diabetes mellitus corresponding odds ratios were 1.0, 0.99
(0.68-1.47), 0.78 (0.51-1.21), and 0.72 (0.48-1.08), respectively, (p for trend 0.07).
However, using a cut point of 150 to define CAC yielded statistically significant results
when subjects with prevalent CHD were excluded: multivariable odds ratios were 1.0, 0.71
(0.48-1.04), 0.63 (0.41-0.98), and 0.54 (0.36-0.82) from the lowest to the highest category of
chocolate intake, respectively (p for trend 0.005).
Discussion
In this study, we demonstrated that chocolate consumption was inversely associated with
prevalent CAC in a dose-response manner. Using other cut points to define prevalent CAC
yielded similar results except when an Agatston score of 0 was used. In addition, exclusion
of subjects with prevalent CHD or diabetes mellitus was suggestive of an inverse association
between chocolate consumption and CAC. To our knowledge, this is the first study to
examine whether chocolate consumption is associated with lower prevalent CAC as
previous observational and interventional studies have focused on the effects of chocolate
consumption on blood pressure, endothelial function, and platelet function. Using the same
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data, we identified an inverse association between chocolate consumption and prevalent
CHD (manuscript under review). While health benefits from chocolate consumption might
have been suspected as early as in the 17th century (mostly in Europe)23, chocolate is not
viewed in the US as a healthy food, but rather as a source of fats and calories23. However,
the literature suggests that moderate consumption of dark chocolate or other flavanoid-rich
foods might have cardiovascular benefits12. In a cross-over design, consumption of 100 g/d
of dark chocolate was associated with a 5.1 mm Hg reduction in systolic blood pressure and
1.8 mm Hg reduction in diastolic blood pressure in 13 hypertensive subjects after 14 days of
intervention10. Another study also demonstrated beneficial effects of dark chocolate on
blood pressure in healthy subjects after a 2-week intervention13. In the Iowa Women's
Health Study24, chocolate contributed 6% of total catechins and when analyzed by catechin
source, there was suggestive evidence for an inverse association between chocolate derived-
catechin and CHD death [RR (95% CI): 0.88 (0.71-1.08)] in a multivariable adjusted model
comparing the 3rd with the 1st tertile of catechin.
Potential physiologic mechanisms by which chocolate might lower the risk of CHD have
been suggested. Besides lowering systolic and diastolic blood pressure10,13,25, dark
chocolate has been shown to transiently but substantially increase nitric oxide bioactivity in
human plasma and reverse endothelial dysfunction26-28. In a randomized trial of 41 diabetic
subjects, a 30-day intervention with flavanol-rich cocoa resulted in a 30% increase in flow-
mediated dilation of the brachial artery29. Furthermore, a prospective cohort reported a 40%
lower risk of cardiovascular risk comparing the fourth to the first quartile of chocolate
consumption and about 12% of that reduction was attributable to beneficial effects of
chocolate on blood pressure30. In addition, dark chocolate was shown to improve insulin
sensitivity and beta cell function in healthy or hypertensive subjects after 15 days of
intervention13,25. Furthermore, there is evidence that chocolate might suppress epinephrine-
stimulated platelet activation and platelet microparticle formation11. Other constituents of
chocolate (magnesium and potassium) have been shown to exert beneficial effects on cell
membrane and blood pressure. It is thus possible that flavonoids in chocolate, alone or in
conjunction with other minerals, might favorably influence the development of
atherosclresosis.
Calcium deposition in the arterial walls occurs in the early stages of atherosclerosis just after
fatty streak formation31 and has been shown to correlate closely with the total burden of
atheroma.1,2 In sensitivity analyses, we observed an inverse association between chocolate
intake and CAC using Agatston scores other than 0 to define prevalent CAC. It is likely that
with a lower Agatston score cut point such as 0, cardiac CT might not have been able to
accurately discriminate the presence or absence of clinically relevant calcified
atherosclerotic plaque in the coronary arteries. This might lead to effect dilution as observed
in this paper. Studies have shown that the use of an Agatston score of 0 as a cut point to
predict angiographic disease (at least 50% stenosis) had a relatively low specificity (up to
40%).3,32 In contrast, using a cut point of 100 had a sensitivity of 93% and a specificity of
76%.3
Our study has limitations. First, although CAC measurement was completed about 7 years
after dietary assessment, we did not have baseline CAC measurement to differentiate
calcification that was present at baseline from calcification that developed after assessment
of chocolate consumption. Thus, our ability to determine temporality or infer causality is
limited. Second, we were not able to differentiate between dark chocolate and lighter or milk
chocolate. Polyphenolic content is higher in dark chocolate than it is in milk chocolate.
Therefore, combining lighter and dark chocolate might have biased our results towards the
null. Lastly, the possibility of confounding by indication (subjects with prevalent CAC or
clinical CHD might have avoided chocolate consumption as bad foods) can not completely
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be excluded in this study. However, the fact that exclusion of subjects with prevalent CHD
showed a similar inverse association (p for trend 0.07 when CAC of at least 100 was used as
cut point and 0.005 when CAC of at least 150 was used as cut point) does not support
confounding by indication as these subjects were free of symptomatic CHD. On the other
hand, the large sample size, the availability of data on major CHD risk factors, and the
standardized techniques used for both CAC and dietary assessment were major strengths of
the study.
In conclusion, our findings indicate that consumption of chocolate might be inversely
associated with prevalent CAC in a dose-response manner. Future studies are warranted to
confirm these findings and elucidate physiologic mechanisms by which moderate
consumption of chocolate (up to 2 servings per week) might positively influence the risk of
atherosclerosis.
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Odds ratios (95% CI) for CAC comparing chocolate consumption of 2+ times per week to
none using different Agatston score cut points to define prevalent CAC (adjusting for age,
sex, smoking, energy, waist-hip ratio, education, ratio of total-to-HDL cholesterol, alcohol
intake, non-chocolate candy, diabetes mellitus, study center, CHD risk group, body mass
index, triglycerides, exercise, and current weight loss diet).
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